# A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP)

> **NCT04578496** · PHASE3 · COMPLETED · sponsor: **Clinuvel Pharmaceuticals Limited** · enrollment: 16 (actual)

## Conditions studied

- Erythropoietic Protoporphyria

## Interventions

- **DRUG:** Afamelanotide

## Key facts

- **NCT ID:** NCT04578496
- **Lead sponsor:** Clinuvel Pharmaceuticals Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07-11
- **Primary completion:** 2014-02-27
- **Final completion:** 2014-02-27
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2020-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04578496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04578496, "A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04578496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*